Reference 2019-402

REF:            2019-402

Subject:        Breast cancer

 

 

Request:

Request 1

Please confirm or deny if Bolton NHS Foundation Trust holds information on the number of people diagnosed in Bolton NHS Foundation Trust with early breast cancer in each year from 2013 to 2018.

If confirm, please release this data.

Request 2

Please confirm or deny if Bolton NHS Foundation Trust holds information on the number of people diagnosed in Bolton NHS Foundation Trust with early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018.

If confirm, please release this data.

Request 3

Please confirm or deny if Bolton NHS Foundation Trust holds information on the number of people diagnosed in Bolton NHS Foundation Trust with early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018.

If confirm, please release this data.

Request 4

Please confirm or deny if Bolton NHS Foundation Trust holds information on the number of people diagnosed in Bolton NHS Foundation Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer in each year from 2013 to 2018.

If confirm, please release this data.

Request 5

Please confirm or deny if Bolton NHS Foundation Trust holds information on the numbers of people diagnosed in Bolton NHS Foundation Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018.

If confirm, please release this data.

Request 6

Please confirm or deny if Bolton NHS Foundation Trust holds information on the number of people diagnosed in Bolton NHS Foundation Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018.

If confirm, please release this data.

 

 

Response:

We hold the information but the information is held in paper records. Refused under section 12 of the Act because will take more than 2.5 to retrieve and collect the information because will involve a manual review.